Such a head-to-head trial was conducted by GlaxoSmithKline to compare their tyrosine kinase inhibitor, pazopanib, to another tyrosine kinase inhibitor, sunitinib, in 1110 patients with metastatic ...

1Department of Urology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Search for other works by this author on: 1Department of Urology, First Affiliated Hospital, Sun Yat-sen ...

Nivolumab plus cabozantinib significantly improved PFS, OS, and ORR compared with sunitinib in patients with advanced RCC. The combination therapy showed a median PFS of 16.4 months vs 8.3 months for ...

Interleukin 2 (IL-2) is the only systemic treatment currently available that is capable of curing patients with metastatic renal cell cancer (RCC). The first indications that IL-2 could mediate ...

PSMA may be a noninvasive biomarker for predicting treatment response in metastatic clear cell renal cell carcinoma (RCC).

近日，湘雅医院皮肤病医院（皮肤科）陈翔教授、刘洪教授等联合在《Nature Genetics》（自然遗传，因子指数31.7）杂志发表了 Alterations in PD-L1 succinylation shape anti-tumor ...

Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...

Oncology nurses play essential roles in the emerging field of cardio-oncology, which aims to protect patients’ heart function ...

Five-year results from a trial examining Exelixis’ Cabometyx as a therapy for previously untreated advanced renal cell carcinoma (RCC) sustaining progression-free (PFS) and overall survival (OS ...

▎药明康德内容团队编辑（来源：中南大学）恶性黑色素瘤是一种以黑色素细胞异常增殖及代谢-免疫失稳态为重要特征的致死性皮肤疾病。尽管免疫检查点抑制剂PD-1/PD-L1单抗显著改善了部分黑色素瘤患者的生存，但其反应率仍不理想，仅有15-25%的跨多种肿瘤 ...

Dr Aggarwal cited the example of cancer-treatment tablets such as Dasatinib, Lenalidomide, Nintedanib and Sunitinib that now cost around ₹4,000 a month. “However, imported drugs cost around ...